RIBC2 and acute myeloid leukemia: Structure–function analysis of TRIB2 revealed that deletion or mutation of the TRIB signature C-terminal E3 ligase COP1-binding site (Figure 4A) prevented TRIB2-mediated degradation of C/EBPα and this correlated directly with a failure to induce AML in vivo[51].